Pfizer Net Income From Continuing Ops from 2010 to 2026
| PFE Stock | EUR 23.37 0.05 0.21% |
Net Income From Continuing Ops | First Reported 2016-12-31 | Previous Quarter 2.9 B | Current Value 3.5 B | Quarterly Volatility 3.3 B |
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Discontinued Operations of 6.6 M, Interest Expense of 3.7 B or Selling General Administrative of 11.2 B, as well as many indicators such as Price To Sales Ratio of 2.16, Dividend Yield of 0.0727 or PTB Ratio of 1.85. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
Pfizer | Net Income From Continuing Ops |
The Net Income From Continuing Ops trend for Pfizer Inc offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Pfizer is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Pfizer's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Pfizer Inc over the last few years. It is Pfizer's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Pfizer Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 11,959,544,118 | |
| Geometric Mean | 10,208,315,667 | |
| Coefficient Of Variation | 60.29 | |
| Mean Deviation | 5,416,338,754 | |
| Median | 9,118,000,000 | |
| Standard Deviation | 7,210,356,439 | |
| Sample Variance | 51989240T | |
| Range | 29.2B | |
| R-Value | 0.23 | |
| Mean Square Error | 52624225.9T | |
| R-Squared | 0.05 | |
| Significance | 0.38 | |
| Slope | 322,613,603 | |
| Total Sum of Squares | 831827839.6T |
Pfizer Net Income From Continuing Ops History
About Pfizer Financial Statements
Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 9.3 B | 14.3 B |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Pfizer Correlation against competitors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.